MCM
ADMA icon

MAI Capital Management’s ADMA Biologics ADMA Stock Holding History

MAI Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.1K Buy
3,456
+879
+34% +$13.9K ﹤0.01% 2539
2025
Q4 		$47K Buy
2,577
+1,352
+110% +$22.8K ﹤0.01% 2047
2025
Q3 		$18K Buy
1,225
+662
+118% +$11.3K ﹤0.01% 2450
2025
Q2 		$10.3K Buy
563
+513
+1,026% +$10.5K ﹤0.01% 2712
2025
Q1 		$992 Buy
+50
New +$865 ﹤0.01% 3135

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

MAI Capital Management's ADMA Position: Q1 2026 in Review

MAI Capital Management increased its ADMA Biologics (ADMA) stake by 34% in Q1 2026, buying an estimated $13.9K and bringing the position to 3,456 shares worth $31.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

MAI Capital Management first reported a position in ADMA in Q1 2025 and has held it in 5 quarters since. The position peaked at $47K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • MAI Capital Management held 3,456 shares of ADMA Biologics worth $31.1K as of Q1 2026.
  • MAI Capital Management bought 879 ADMA Biologics shares in Q1 2026, an estimated $13.9K.
  • ADMA Biologics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #2539 holding.
  • MAI Capital Management first reported a position in ADMA Biologics in Q1 2025 and has held it in 5 quarters since.
  • MAI Capital Management's ADMA Biologics position peaked at $47K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.